Early Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes: Study Based on Continuous Glucose Monitoring

Diabetology and Metabolic Syndrome- United Kingdom

doi 10.1186/s13098-017-0258-5

Full Text

Abstract

Available in

Categories

Internal Medicine

Date

August 4, 2017

Authors

Keiichi Torimoto

Publisher

Springer Science and Business Media LLC

Related search

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

US Endocrinology

English

The Potential Role of Sodium Glucose Co-Transporter 2 Inhibitors in the Early Treatment of Type 2 Diabetes Mellitus

International Journal of Clinical Practice

English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?

English

Sodium-Glucose Co-Transporter Type-2 Inhibitors: Pharmacology and Peri-Operative Considerations

English

Sodium-Glucose Co-Transporter 2 Inhibitors: A Review of Their Use in Older People With Type 2 Diabetes Mellitus

Journal of Pharmacy Practice and Research

English

Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis

English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through? A Reply

English

Should Sodium Glucose Co-Transporter 2 Inhibitors Be Considered as First Line Oral Therapy for People With Type 2 Diabetes?

Diabetes, Obesity and Metabolism

Internal Medicine

English

Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Drugs in Context

Molecular Medicine

English